Snapshot 3D Ultra-high-resolution OCT and Hyperspectral AF of In-vivo Retina

Status: Active_not_recruiting
Location: See location...
Intervention Type: Diagnostic test
Study Type: Observational
SUMMARY

This study proposes to use a new instrument (AO-OCT/AF: adaptive optics - optical coherence tomography/autofluorescence) combined with a data processing method to image the retinal pigment epithelium (RPE) of the eye in normal subjects and in subjects with age-related macular degeneration. (AMD). While currently there is no cure, with early diagnosis, vision loss can be slowed. The technology being developed for this project will be the first imaging modality that can provide both structural and molecular information about the retina in vivo and in 3D.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 60
Maximum Age: 90
Healthy Volunteers: t
View:

• Patients must be aged 60 and over and pseudophakic, with clear posterior capsule and dilation to 6mm.

• Patients must be diagnosed early/intermediate AMD in at least one eye (the study eye) with soft drusen or reticular pseudodrusen in the macula.

Locations
United States
New York
New York Eye and Ear Infirmary of Mount Sinai
New York
Time Frame
Start Date: 2023-09-06
Completion Date: 2025-12
Participants
Target number of participants: 50
Treatments
Normals
Imaging normal subjects for equipment refinement
Subjects with AMD
Imaging subjects with AMD
Sponsors
Leads: Icahn School of Medicine at Mount Sinai
Collaborators: National Eye Institute (NEI), University of California, Los Angeles

This content was sourced from clinicaltrials.gov

Similar Clinical Trials